ClinicalTrials.gg
RecruitingNCT06906588BILAXUpdated Oct 19, 2026

Bilateral Robot-assisted Upper Extremity Rehabilitation on Motor Recovery in People With Subacute Stroke

An interventional study of Experimental and Control in Stroke and Sabacute Stroke, sponsored by IRCCS San Raffaele Roma. Recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by IRCCS San Raffaele Roma · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled May 2024, registered Mar 2025).
  • Started May 2024; still recruiting 2 years 6 months later.
Updated Oct 19, 2026Primary completion moved3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stroke by IRCCS San Raffaele Roma — 4 open to participants now, 5 under way, none of them phase 3. Stroke · IRCCS San Raffaele Roma.

Started
2024
the only one that year
No phase
9 of 12
3 open now
Registered
10th of 12
by date

Among the 12 studies in Stroke by IRCCS San Raffaele Roma, this one is the only one that started in 2024, is one of 9 with no phase, and was the 10th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 12 studies in Stroke by IRCCS San Raffaele Roma are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stroke by IRCCS San Raffaele Roma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to study the clinical effects of a robotic rehabilitation treatment through a bilateral exoskeleton (Bilateral Robot-Assisted Therapy-BRAT) during standard rehabilitation, on motor recovery, compared to conventional arm re-education in people suffering from stroke in the subacute phase. The main question it aims to answer is what the effectiveness of Bilateral Robot-Assisted Therapy (BRAT) is in rehabilitating the upper limb in individuals with subacute stroke compared to conventional rehabilitation treatment in terms of motor function improvement as measured by the Fugl-Meyer Assessment - Upper Limb (FMA-UL), motor domain. Researchers will compare two groups (Experimental Group - EG and Control Group - CG) to see if the BRAT is more effective than conventional rehabilitation treatment in terms of motor recovery. Participants will be randomly assigned to one of the two treatment groups (EG or CG) and will be clinically and instrumentally evaluated at baseline (T0) and at the end of treatment (T1). EG, in addition to the standard rehabilitation treatment, will perform a 45-minute session of BRAT per day through the Arm Light Exoskeleton Hybrid (Alex RS - Wearable Robotics) robotic system. The CG, in addition to the standard routine rehabilitation treatment, will follow a conventional rehabilitation of the upper limbs without the use of technological devices. Finally, a telephone follow-up is scheduled three months after the end of the treatment.

Read the detailed description

Cerebral stroke is one of the major causes of mortality and disability in the world. Upper limb disorders are evident up to 85% of stroke survivors and persist, even 6 months after the acute event, in 55-75% of patients. Recovery of upper limb ability represents a major challenge for neurorehabilitation. Among recent strategies and trends in stroke rehabilitation, robotic technologies are having more space and their application in clinical routine is increasing. The promising effects of robot-assisted therapy for upper limb rehabilitation (Robot-Assisted Therapy-RAT) have been demonstrated in terms of recovery of arm and hand range of motion, muscle strength, thus improving performance of activities of daily living (AVQ). In particular, the latest generation exoskeletal robots have demonstrated their effectiveness, promoting a three-dimensional rehabilitation activity. At the same time, bimanual therapy represents a different training modality which has its solid neuroscientific foundations to improve learning and positively address neuroplasticity phenomena. However, there is no information regarding the effectiveness of these robots on subjects suffering from stroke and in the subacute phase. The primary objective of this RCT is to study the clinical effects of upper limb rehabilitation through a bilateral exoskeleton (Bilateral Robot-Assisted Therapy-BRAT) within standard rehabilitation, on motor recovery, compared to conventional arm re-education in people suffering from stroke in the subacute phase. Secondary objectives of the study include: evaluation of the effectiveness of BRAT on bilateral recovery of arm motor skills and quality of life of study participants; the identification of the characteristics of patients who can benefit most from BRAT in terms of age, distance from the acute event and extent of the motor deficit of the upper limb. The effects of BRAT on motor recovery will also be studied from a neurophysiological (EEG and sEMG) and biomechanical (Inertial Measurement Units-IMU) point of view.The study will develop over 24 months, and includes 3 phases as follows: Phase 1- patient enrollment and screening; Phase 2 Treatment of participants; Phase 3 - Statistical analysis of the data. The study protocol will involve people diagnosed with stroke according to established inclusion and exclusion criteria who will be randomly assigned to one of the following groups: Experimental Group (EG) - robotic treatment for upper limb rehabilitation or Control Group (CG) - conventional treatment for upper limb rehabilitation. The experimental group (EG), in addition to the standard rehabilitation treatment, will perform one BRAT session per day through the Arm Light Exoskeleton Hybrid (Alex RS - Wearable Robotics) robotic system. Each participant will perform a total of 16+/-3 treatment sessions with a frequency of 4 times a week for 4 consecutive weeks. All the devices that will be used have the CE (European Conformity) marking. The control group (CG), in addition to the standard routine rehabilitation treatment, will follow a conventional rehabilitation of the upper limbs (16+/-3 treatment sessions) without the use of technological devices. The motor exercises will concern the rehabilitation of the upper limb and will be performed with a therapist who will personalize the treatment based on the clinical characteristics and needs of the patient. Specifically, the treatment of the upper limb will be characterized by motor exercises (shoulder, elbow, wrist and hand), coordination and manual dexterity. All subjects will be evaluated with a standard clinical objective examination and with clinical rating scales and instrumental assessments. These scales will be administered at baseline (T0), at the end of treatment (T1) and 3 months after the end of treatment (follow-up). The main expected results are: identify a customizable rehabilitation protocol for motor recovery of the upper limb based on the clinical characteristics of each individual patient; achieve better motor recovery both in terms of range of motion and muscle recruitment associated with cognitive stimulation following upper limb rehabilitation through the Alex exoskeleton bilateral robotic assistance system; achieve better muscle activation and therefore better motor performance in the EG; achieve greater autonomy in carrying out daily life activities and consequently greater participation.

03

Conditions studied

  • Stroke
  • Sabacute Stroke

Browse trials for

Keywords

  • Upper limb rehabilitation
  • Bilateral Robot-Assisted Therapy-BRAT
  • stroke
  • subacute
  • Robotic rehabilitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both sexes;
  • Age >18 years;
  • Unilateral hemipyramidal syndrome as demonstrated by a brain CT or MRI;
  • Distance from acute event \< 6 months;
  • Modified Ashworth Scale (MAS) of shoulder, elbow, and wrist \<3;
  • Ability to understand and sign the for the study;
  • Ability to perform the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Unstable general clinical conditions;
  • Bilateral pyramidal hemisyndrome severe visual impairment;
  • Recent injection of Botulinum Toxin to the affected upper limb or planned for the duration of the study;
  • Interruption of treatment for 1 week or 5 consecutive sessions;
  • Inability to adhere to the exercise program due to poor compliance;
  • Presence of neurological pathologies superimposed on the stroke event, psychiatric complications or personality disorders;
  • Presence of osteoarticular and neuromuscular pathologies that may compromise the motor skills of the upper limb;
  • Participants who have not signed the to the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Experimental Group (EG)

    The experimental group (EG), in addition to the standard rehabilitation treatment, will perform one Bilateral Robot-Assisted Therapy-BRAT session per day through the Arm Light Exoskeleton Hybrid (Alex RS - Wearable Robotics) robotic system. Each participant will perform a total of 16+/-3 treatment sessions. The device that will be used have the CE (European Conformity) marking.

    Device: Experimental

  • Active comparator
    Control Group (CG)

    The control group (CG), in addition to the standard routine rehabilitation treatment, will follow 45 minutes of conventional rehabilitation of the upper limbs without the use of technological devices. Each participant will perform a total of 16+/-3 conventional upper limb treatment sessions. The motor exercises will concern the rehabilitation of the upper limb and will be performed with a therapist who will personalize the treatment based on the clinical characteristics and needs of the patient.

    Other: Control

Interventions

  • DeviceExperimental

    The experimental group (EG), in addition to the standard rehabilitation treatment, will perform one upper limb BRAT session per day through the Arm Light Exoskeleton Hybrid (Alex RS - Wearable Robotics) robotic system.. Each participant will perform a total of 16+/-3 treatment sessions with a frequency of 4 times a week for 4 consecutive weeks. During the first session, the device should be adjusted according to the patient's bilateral size and suspension angle. The selection of personalized exercises will be based on each patient's motor skills and the difficulty can be gradually increased during the treatment period. These modalities are shown to the patient with visual and motor feedback (force feedback). The duration of the single rehabilitation treatment is 45 minutes, of which 5 minutes are used for setting up the device, 10 minutes for assembly/disassembly, 10 minutes for unilateral treatment with the affected upper limb and 20 minutes for bilateral treatment.

  • OtherControl

    The control group (GC), in addition to the standard routine rehabilitation treatment, will follow 45 minutes of conventional rehabilitation of the upper limbs without the use of technological devices. Each participant will perform a total of 16+/-3 conventional upper limb treatment sessions with a frequency of 4 times a week for 4 weeks. The motor exercises will concern the rehabilitation of the upper limb and will be performed with a therapist who will personalize the treatment based on the clinical characteristics and needs of the patient. Specifically, the treatment of the upper limb will be characterized by motor exercises (shoulder, elbow, wrist and hand), coordination and manual dexterity. Each session will consist of passive, active-assisted and active exercises.

06

What researchers measure

Primary outcomes

  1. Upper Limb Fugle Meyer Assessment - Motor Part (score range: 0-66)

    The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treatment. The Fugl-Meyer Assessment (FMA) is a widely used clinical tool to assess motor recovery in individuals who have experienced a stroke. It is designed to measure motor function, sensory function, balance, and joint range of motionin individuals with hemiplegia (one-sided paralysis or weakness), which is common following a stroke.

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

Secondary outcomes

  1. Oxford Cognitive Scale (OCS)

    The Oxford Cognitive Screen (OCS) assesses key cognitive domains: memory, language, numerical cognition, praxis, executive functions, and attention. It is designed as a screening tool that enables a rapid evaluation of the patient's cognitive functioning and guides further, more detailed assessment of any impaired cognitive domain(s). It also allows for the evaluation of aphasic patients. Test items are presented both visually and verbally, with the option to select a correct response from multiple choices. To optimize the distribution of attentional resources, the battery items are presented centrally, reducing the need for visual scanning. The OCS allows for the assessment of neglect (both allocentric and egocentric), apraxia, and deficits in numerical cognition.

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

  2. Modified Ashworth Scale (MAS) 0-4

    The Modified Ashworth Scale (MAS) is used to assess spasticity. The Modified Ashworth Scale (MAS) has been utilised in the following populations: stroke, spinal cord injury, multiple sclerosis, cerebral palsy, traumatic brain injury, paediatric hypertonia and central nervous system lesions. The test is performed by extending the patients limb's first from a position of maximal possible flexion to maximal possible extension (the point at which the first soft resistance is met). Afterwards, the modified Ashworth scale is assessed while moving from extension to flexion. Scores range from 0 to 4, where 0 indicates no increase in muscle tone and 4 represents a limb that is rigid in flexion or extension. The score from 0 to 4 indicated in the title refers to the individual joint. Specifically, in this study, the muscle tone of the shoulder, elbow, and wrist will be assessed.

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

  3. Box and Block test (BBT)

    The Box and Block Test (BBT) measures unilateral gross manual dexterity. It can be used with a wide range of populations, including clients with stroke.The BBT is composed of a wooden box divided in two compartments by a partition and 150 blocks. The BBT administration consists of asking the client to move, one by one, the maximum number of blocks from one compartment of a box to another of equal size, within 60 seconds.

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

  4. Nine Hole Peg Test (NHPT)

    The Nine-Hole Peg Test (9HPT) is used to measure finger dexterity in patients with various neurological diagnoses. The Nine-Hole Peg Test is administered by asking the client to take the pegs from a container, one by one, and place them into holes on the board as quickly as possible. Participants must then remove the pegs from the holes, one by one, and replace them back into the container.Scores are based on the time taken to complete the activity, recorded in seconds.

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

  5. ABILHAND

    The ABILHAND is an interview-based assessment of a patient-reported measure of the perceived difficulty in using their hand to perform manual activities in daily activities. The assessment considers the active function of the upper limbs and measures the ability to perform bimanual tasks, regardless of the way in which these tasks are carried out. There are currently versions specifically validated for Chronic stroke, Rheumatoid Arthritis, Systemic sclerosis, Hand Surgery. This is an interview-based assessment where patient is asked to estimate the ease or difficulty of performing a list of activities when carried out without assistance. This can involve any strategy used to carry out the activity, and is self-report and not a physical demonstration of the activity. The questionnaire is downloaded from the website and one of the 10 random orders of questions. These are read to the patient and scored as either "impossible", "difficult" or "easy". If a task has not been attempted

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

  6. Modified Barthel Index (mBI)

    The modified Barthel Index (mBI) is a well-established patient-centered outcome measure commonly administrated in rehabilitation settings to evaluate the functional status of patients at admission and discharge.

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

  7. Client Satisfaction Questionnaire (0-24)

    The Client Satisfaction Questionnaire (CSQ-8) is one of a limited number of standardised satisfaction measures that have been used widely across mental health services.

    Time frame: Day 28 (T1 - After treatment)

  8. Frenchay Activities Index (FAI)

    The Frenchay Activities Index (FAI) is a measure of instrumental activities of daily living (IADL) for use with patients recovering from stroke. The FAI assesses a broad range of activities associated with everyday life that patient has participated in within the recent past, broken into 3 domains: domestic chores, leisure/work, and outdoor activities. The items included move beyond the scope of ADL scales, which tend to focus on issues related to self care and mobility. Can be separated into 3 domains: 1. Domestic chores 2. Leisure/work 3. Outdoor activities The frequency with which each item or activity is undertaken over the past 3-6 months (depending on the nature of the activity) is assigned a score of 1 - 4 where a score of 1 is indicative of the lowest level of activity. The scale provides a summed score from 15 - 60.

    Time frame: Day 120 (T2 - 3 months after treatment Follow-Up)

  9. Disability of the Arm, Shoulder, and Hand (DASH) Questionnarie

    The Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire is a 30-item questionnaire that looks at the ability of a patient to perform certain upper extremity activities. This questionnaire is a self-report questionnaire that patients can rate difficulty and interference with daily life on a 5 point Likert scale. It has two, 4-item, optional modules used to measure symptoms and function in athletes, artists, and workers who require a high level of function. Utilizes a 5-point Likert-Scale measuring from "1" (lowest level of difficulty or severity) to 5" (highest level of difficulty or severity) based on the patient's reported ability to conduct the activities or tasks. Total scores range from 0 (minimum) to (100) maximum.

    Time frame: Day 120 (T2 - 3 months after treatment Follow-Up)

Other outcomes

  1. Instrumental robotic assessment

    A robotic assessment will be performed only for the subjects in the GS group. The robotic device used in the study allows for the evaluation of: Preliminary measurement of the force exerted by the patient during each movement (isometric contraction); Pre-post measurements of the active Range of Motion (ROM) in the patient's 3D working area and of all the individual joints of the affected arm (constrained joints); Movement precision pre-post (speed peaks recorded during exercises).

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

  2. Instrumental neurophysiological assessments

    In a subgroup of GS subjects (neurophysiological pilot study), instrumental assessments of neurophysiological signals will also be performed at centers equipped with the appropriate instruments. Surface electromyography (sEMG) and kinematics (stereophotogrammetric system with the RAB protocol) will be recorded during the execution of a standardized motor task (Reaching). Electroencephalography (EEG): Brain electrical activity will be recorded from 120 channels during rest conditions with eyes closed and open (5 minutes each). The frequency bands considered will be delta (2-4 Hz), theta (4-8 Hz), Alpha1 (8-10.5 Hz), alpha2 (10.5-13 Hz), beta1 (13-20 Hz), beta2 (20-30 Hz), and gamma (30-40 Hz). The activation current density of cortical sources and brain connectivity will be calculated with the eLORETA software for both hemispheres. Specific networks related to the task performed and the lesioned areas will also be analyzed.

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

  3. IMU-based targeted Box and Block Test (t-BBT)

    Instrumental assessment of manual dexterity will be conducted using a sensorized and modified version of the Box and Block Test (BBT). This modified version involves moving 10 cubes from one side of the box to the other positioned on a 5x2 grid. In a subset of EG subjects, kinematic parameters will be measured using Inertial Measurement Units (IMUs), and electrophysiological parameters will be recorded via surface electromyography (sEMG). The assessment will quantify joint kinematics, including range of motion and movement smoothness, as well as upper limb muscle activation patterns, such as muscle onset timing and co-contraction levels. This approach enables a comprehensive evaluation of motor performance during the BBT.

    Time frame: Day 0 (T0- basline) and day 28 (T1 - After treatment)

07

Study locations

1 of 3 sites recruiting
  • San Raffaele Cassino
    Cassino, Italy 03043, Italy
    Not yet recruiting
    • Prof. Maria Francesca De Pandis, MD, PhD · Contactmaria.depandis@sanraffaele.it · +39 0776 394740
    • Prof. Maria Francesca De Pandis, MD, PhD · Principal investigator
  • IRCCS San Raffaele Roma
    Rome, Italy 00166, Italy
    Recruiting
    • Dr. Sanaz Pournajaf, DPT, PhD (cand.) · Contactsanaz.pournajfa@sanraffaele.it · +39 0652252405
    • Dr. Sanaz Pournajaf, DPT, PhD · Principal investigator
  • San Raffaele Sulmona
    Sulmona, Italy 67039, Italy
    Not yet recruiting
08

References and documents

Publications

  • Kwakkel G, Kollen BJ, van der Grond J, Prevo AJ. Probability of regaining dexterity in the flaccid upper limb: impact of severity of paresis and time since onset in acute stroke. Stroke. 2003 Sep;34(9):2181-6. doi: 10.1161/01.STR.0000087172.16305.CD. Epub 2003 Aug 7. PubMed 12907818 ↗
  • Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. Cochrane Database Syst Rev. 2018 Sep 3;9(9):CD006876. doi: 10.1002/14651858.CD006876.pub5. PubMed 30175845 ↗
  • Morone G, Palomba A, Martino Cinnera A, Agostini M, Aprile I, Arienti C, Paci M, Casanova E, Marino D, LA Rosa G, Bressi F, Sterzi S, Gandolfi M, Giansanti D, Perrero L, Battistini A, Miccinilli S, Filoni S, Sicari M, Petrozzino S, Solaro CM, Gargano S, Benanti P, Boldrini P, Bonaiuti D, Castelli E, Draicchio F, Falabella V, Galeri S, Gimigliano F, Grigioni M, Mazzoleni S, Mazzon S, Molteni F, Petrarca M, Picelli A, Posteraro F, Senatore M, Turchetti G, Straudi S; "CICERONE" Italian Consensus Conference on Robotic in Neurorehabilitation. Systematic review of guidelines to identify recommendations for upper limb robotic rehabilitation after stroke. Eur J Phys Rehabil Med. 2021 Apr;57(2):238-245. doi: 10.23736/S1973-9087.21.06625-9. Epub 2021 Jan 25. PubMed 33491943 ↗
  • Iosa M, Morone G, Ragaglini MR, Fusco A, Paolucci S. Motor strategies and bilateral transfer in sensorimotor learning of patients with subacute stroke and healthy subjects. A randomized controlled trial. Eur J Phys Rehabil Med. 2013 Jun;49(3):291-9. Epub 2012 Nov 20. PubMed 23172404 ↗
  • Frisoli A, Barsotti M, Sotgiu E, Lamola G, Procopio C, Chisari C. A randomized clinical control study on the efficacy of three-dimensional upper limb robotic exoskeleton training in chronic stroke. J Neuroeng Rehabil. 2022 Feb 4;19(1):14. doi: 10.1186/s12984-022-00991-y. PubMed 35120546 ↗
  • Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2011;9(8):672-7. doi: 10.1016/j.ijsu.2011.09.004. Epub 2011 Oct 13. No abstract available. PubMed 22019563 ↗
  • Calabro RS, Naro A, Russo M, Milardi D, Leo A, Filoni S, Trinchera A, Bramanti P. Is two better than one? Muscle vibration plus robotic rehabilitation to improve upper limb spasticity and function: A pilot randomized controlled trial. PLoS One. 2017 Oct 3;12(10):e0185936. doi: 10.1371/journal.pone.0185936. eCollection 2017. PubMed 28973024 ↗
  • Demeyere N, Riddoch MJ, Slavkova ED, Bickerton WL, Humphreys GW. The Oxford Cognitive Screen (OCS): validation of a stroke-specific short cognitive screening tool. Psychol Assess. 2015 Sep;27(3):883-94. doi: 10.1037/pas0000082. Epub 2015 Mar 2. PubMed 25730165 ↗
  • Mancuso M, Varalta V, Sardella L, Capitani D, Zoccolotti P, Antonucci G; Italian OCS Group. Italian normative data for a stroke specific cognitive screening tool: the Oxford Cognitive Screen (OCS). Neurol Sci. 2016 Oct;37(10):1713-21. doi: 10.1007/s10072-016-2650-6. Epub 2016 Jul 9. PubMed 27395388 ↗

Individual participant data

Plan to share: Yes — Individual participant data (IPD) will be shared with qualified researchers upon reasonable request, following ethical and regulatory approvals.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Individual participant data (IPD) will be available upon publication of the main results and will remain accessible for at least five years.

Access criteria: Qualified researchers may request access to the data by submitting a proposal outlining their research objectives. Access will be granted upon ethical and regulatory approval and under a data-sharing agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 31 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Dec 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 2, 2025
StartActual
May 19, 2024
Primary completionEst.
Dec 31, 2026was Dec 2025
CompletionEst.
Dec 31, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (3 Italy)
  • San Raffaele Cassino · Cassino, Italy
  • IRCCS San Raffaele Roma · Rome, Italy
  • San Raffaele Sulmona · Sulmona, Italy
Show 3 removed
  • San Raffaele Cassino · Cassino, Italy
  • IRCCS San Raffaele Roma · Rome, Italy
  • San Raffaele Sulmona · Sulmona, Italy
Oct 19, 2026
Primary completion
Dec 31, 2025→Dec 31, 2026
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    3 sites added, 3 sites removed
    Show 3 added (3 Italy)
    • San Raffaele Cassino · Cassino, Italy
    • IRCCS San Raffaele Roma · Rome, Italy
    • San Raffaele Sulmona · Sulmona, Italy
    Show 3 removed
    • San Raffaele Cassino · Cassino, Italy
    • IRCCS San Raffaele Roma · Rome, Italy
    • San Raffaele Sulmona · Sulmona, Italy
    Primary completion Dec 31, 2025→Dec 31, 2026
    + 3 other changes: index terms, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06906588
Lead sponsor
IRCCS San Raffaele Roma
Collaborators
Ministry of Health, Italy
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
May 19, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 19, 2026

Study contacts

Dr. Sanaz Pournajaf, DPT
Contact
sanaz.pournajaf@sanraffaele.it
+39-06-52252405 ext. 32405
Dr. Elena Sofia Cocco, Bioengineer
Contact
elenasofia.cocco@sanraffaele.it
Dr. Sanaz Pournajaf, DPT
principal investigator · IRCCS San Raffaele Roma
Prof. Marco Franceschini, MD
study chair · IRCCS San Raffaele Roma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion